21.86
-0.22
(-1.00%)
At close: April 17 at 4:00:02 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 9 | 8 | 10 | 10 |
| Avg. Estimate | 0.1 | 0.12 | 0.58 | 0.71 |
| Low Estimate | 0.09 | 0.11 | 0.56 | 0.69 |
| High Estimate | 0.11 | 0.13 | 0.62 | 0.74 |
| Year Ago EPS | 0.09 | 0.1 | 0.52 | 0.58 |
Revenue Estimate
| Currency in EUR | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 8 | 7 | 10 | 10 |
| Avg. Estimate | 247.48M | 273.06M | 1.17B | 1.3B |
| Low Estimate | 242M | 270.2M | 1.17B | 1.26B |
| High Estimate | 253.03M | 277.03M | 1.19B | 1.32B |
| Year Ago Sales | 236M | 259.6M | 1.1B | 1.17B |
| Sales Growth (year/est) | 4.87% | 5.18% | 6.42% | 10.46% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.12 | 0.11 | 0.14 | 0.19 |
| EPS Actual | 0.09 | 0.1 | 0.13 | 0.2 |
| Difference | -0.03 | -0.01 | -0.01 | 0.01 |
| Surprise % | -27.90% | -6.74% | -6.01% | 5.58% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0.1 | 0.12 | 0.58 | 0.71 |
| 7 Days Ago | 0.1 | 0.12 | 0.58 | 0.71 |
| 30 Days Ago | 0.1 | 0.12 | 0.58 | 0.71 |
| 60 Days Ago | 0.1 | 0.12 | 0.57 | 0.71 |
| 90 Days Ago | 0.1 | 0.12 | 0.57 | 0.72 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 2 | 5 |
| Down Last 7 Days | 1 | -- | 1 | -- |
| Down Last 30 Days | 1 | -- | 1 | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| STVN | 14.85% | 24.94% | 12.63% | 22.51% |
| S&P 500 | 6.92% | 4.87% | 8.58% | 14.16% |
Upgrades & Downgrades
| Maintains | UBS: Neutral to Neutral | 3/7/2025 |
| Maintains | B of A Securities: Buy to Buy | 12/13/2024 |
| Initiated | Wolfe Research: Outperform | 12/13/2024 |
| Maintains | Citigroup: Buy to Buy | 8/7/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 7/15/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 4/22/2024 |
Related Tickers
1SXP.DE SCHOTT Pharma AG & Co. KGaA
23.05
+1.54%
ATR AptarGroup, Inc.
143.83
-0.81%
GXI.DE Gerresheimer AG
51.85
+2.07%
RGEN Repligen Corporation
130.00
-1.59%
HOCPY HOYA Corporation
108.35
+1.17%
WST West Pharmaceutical Services, Inc.
201.90
-3.46%
AVTR Avantor, Inc.
15.10
-0.98%
UTMD Utah Medical Products, Inc.
52.30
-0.19%
ICUI ICU Medical, Inc.
138.67
-0.34%
ANGO AngioDynamics, Inc.
9.52
+0.63%